Acetylcysteine/pentoxifyllineAlternative Names: Acetylcysteine/oxpentifylline; Oxpentifylline/acetylcysteine; Pentoxifylline/acetylcysteine; PTL-202
Latest Information Update: 27 Jun 2015
At a glance
- Originator Pacific Therapeutics
- Class Antifibrotics; Reducing agents; Small molecules; Sulfur amino acids; Xanthines
- Mechanism of Action Antioxidants; Cytokine inhibitors; Free radical scavengers; Phosphoric diester hydrolase inhibitors; Platelet aggregation inhibitors; Transforming growth factor beta inhibitors; Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis